SB 694, the PLASMA Act, would amend the Medicare Part D manufacturer discount program to create a phased-in discount schedule for plasma-derived products. The bill applies to certain biological products derived from human whole blood or plasma that were already marketed as of August 16, 2022, and dispensed to Medicare Part D beneficiaries. Instead of immediately subjecting these products to the full manufacturer discount requirements, the bill would set a reduced “discounted price” for these drugs beginning in 2026 and gradually lower the percentage over time.
The phase-in differs depending on whether a beneficiary has reached the annual out-of-pocket threshold for Part D drugs. For beneficiaries below the threshold, the discount would step down from 99 percent in 2026 to 90 percent by 2030 and later. For beneficiaries who have already reached the threshold, the phase-in would continue further, eventually reaching 80 percent in 2032 and thereafter. The bill also excludes certain drugs dispensed to low-income subsidy beneficiaries and certain small-manufacturer drugs from this special phase-in treatment.
In practical terms, the bill would modify how Medicare Part D discounts are calculated for a narrow class of specialty medicines, likely reducing the immediate financial burden on manufacturers of plasma-derived therapies while preserving beneficiary access. It would amend section 1860D-14C(g)(4) of the Social Security Act, affecting Medicare prescription drug pricing rules and the manufacturer discount program administered under federal law.
The available context suggests generally supportive or at least noncontroversial treatment at introduction: the bill was introduced by Senators Tillis and Kelly and referred to the Senate Committee on Finance, with no recorded votes or committee debate provided. Because no transcript or vote history is available, there is no documented opposition in the supplied materials. The bill’s title and structure indicate a policy goal of protecting access to life-saving specialty medicines, which is likely the main rationale behind the proposal.
The main point of potential contention is the policy tradeoff between lowering manufacturer obligations under Medicare and maintaining affordability for beneficiaries and program costs. Supporters would likely emphasize access and supply stability for plasma-derived therapies, while critics could question whether the phase-in creates unequal treatment for a subset of drugs or delays full discount obligations under Medicare.
Impact
SB 694 would amend the Social Security Act’s Medicare Part D manufacturer discount provisions, specifically section 1860D-14C(g)(4), to add a new phased-in discount rule for plasma-derived products. It would create a special pricing formula for certain biological products derived from human blood or plasma that were marketed by August 16, 2022, and would exempt those products from the standard immediate discount treatment for a defined period. The bill would affect Medicare Part D manufacturers, plan pricing calculations, and beneficiaries receiving these specialty medicines, while preserving existing exclusions for low-income subsidy drugs and certain small manufacturers.
Sentiment
The bill appears generally favorable in the limited record provided. It was introduced with a policy framing centered on preserving access to life-saving specialty medicines and was referred to the Senate Finance Committee without any recorded vote or stated opposition in the supplied materials. Because there are no committee transcripts or vote tallies, the available context does not show organized controversy, though the bill’s targeted relief for plasma-derived products suggests a deliberate effort to balance access concerns with Medicare discount policy.
Contention
The likely contention is whether plasma-derived products should receive a special, phased-in treatment under the manufacturer discount program rather than being subject immediately to the standard discount structure. Supporters would likely argue that these therapies are essential, specialized, and vulnerable to supply or access disruptions if discounts are imposed too quickly. Potential critics may argue that the bill creates a carve-out for a narrow class of drugs, could reduce savings for Medicare, and may complicate the uniform application of Part D manufacturer discount rules. No specific opposing lawmakers or stakeholder groups are identified in the provided materials.